PDF
Full
Outline
To observe the clinical efficacy and safety of insulin degludec and liraglutide combination with metformin tablets in the treatment of type 2 diabetes mellitus (T2DM) patients with poorly controlled insulin and oral hypoglycemic drugs.
The T2DM patients with poor control of insulin and oral hypoglycemic drugs were randomly divided into control group and treatment group according to the queue method. Both groups of patients received metformin tablets for basic treatment. On this basis, the control group was given premixed insulin aspartic 30 injection multiple times a day for treatment. The initial injection dose was 0.2-0.4 U·kg-1·d-1, twice a day, adjusted according to the blood glucose level, once every 3-5 days, with an increase or decrease of 1-4 U each time. The treatment group was treated with insulin degludec and liraglutide injection. The initial injection was 10 to 16 dose units, administered subcutaneously once a day. The dose was adjusted every 1 to 2 weeks based on the blood glucose level, with an increase or decrease of 2 to 4 dose units each time. Both groups of patients were treated for 3 months. The clinical efficacy, blood glucose level, lipid metabolism level, pancreatic islet function and safety of the two groups of patients were compared.
A total of 40 cases in the control group and 40 cases in the treatment group were enrolled. After treatment, the total effective rates of the treatment group and the control group were 97.50% (39 cases/40 cases) and 80.00% (32 cases/40 cases), the difference was statistically significant (P<0.05). After 3 months of treatment, the glycosylated hemoglobin levels of the treatment group and the control group were (6.14±1.03)% and (7.20±1.08)%, respectively; the fasting blood glucose levels were (6.25±1.34) and (7.82±1.26) mmol·L-1, respectively; the 2 h postprandial blood glucose levels were (6.37±0.64) and (7.15±0.67) mmol·L-1, respectively; the triglyceride levels were (1.87±0.62) and (2.64±0.79) mmol·L-1, respectively; the serum total cholesterol levels were (4.53±0.62) and (5.18±0.76) mmol·L-1, respectively; and the fasting insulin levels were (7.16±0.71) and (8.56±0.94) μmol·L-1, respectively; islet β cell function index levels were (58.36±5.87)% and (50.72±6.14)%, respectively; while insulin resistance index levels were 1.52±0.44 and 2.09±0.47, respectively, the differences were statistically significant between the two groups (all P<0.05). The main adverse drug reactions in the treatment group were gastrointestinal reactions, dizziness, increased heart rate and hypoglycemia, while those in the control group were mainly gastrointestinal reactions, dizziness and hypoglycemia. The total incidences of adverse drug reactions in the treatment group and the control group were 15.00% and 12.50%, respectively, and there was no statistically significant difference (P>0.05).
Insulin degludec and liraglutide injection has shown significant clinical efficacy in the treatment of T2DM with poor control of insulin and oral hypoglycemic drugs. It can effectively control patients’ blood glucose and lipid metabolism levels, improve pancreatic function, and has good safety.
PDF
562
446
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
